Lungpacer Medical, Inc.
Lungpacer Medical is dedicated to developing minimally invasive neurostimulation technologies to help patients wean off mechanical ventilation and breathe independently. Their flagship product, the AeroPace System, is designed to stimulate the nerves that activate and exercise the diaphragm, aiming to rebuild diaphragm strength and facilitate faster ventilator weaning. The company is also developing the AeroNova System, which utilizes continuous diaphragm stimulation to reduce ventilator-induced injury. Lungpacer's mission is to improve patient outcomes, reduce healthcare costs, and transform the future of ventilation through innovative neurostimulation therapies.
Industries
Nr. of Employees
medium (51-250)
Lungpacer Medical, Inc.
Vancouver, British Columbia, Canada, North America
Products
Catheter-based diaphragm neurostimulation system (FDA PMA approved for ventilator weaning support)
A system composed of a bedside stimulation console and a multi-lumen transvenous catheter with embedded electrodes designed to deliver periodic phrenic nerve stimulation to strengthen the diaphragm and support weaning in adult patients on prolonged mechanical ventilation. Reported regulatory approval includes U.S. FDA premarket approval for specified adult weaning indications.
Investigational continuous diaphragm stimulation system (in clinical investigation)
An investigational catheter-based system and software designed to provide continual, ventilation-synchronized diaphragm stimulation aimed at achieving physiologic breathing patterns and potentially mitigating ventilator-induced injury; currently evaluated under investigational device protocols.
Catheter-based diaphragm neurostimulation system (FDA PMA approved for ventilator weaning support)
A system composed of a bedside stimulation console and a multi-lumen transvenous catheter with embedded electrodes designed to deliver periodic phrenic nerve stimulation to strengthen the diaphragm and support weaning in adult patients on prolonged mechanical ventilation. Reported regulatory approval includes U.S. FDA premarket approval for specified adult weaning indications.
Investigational continuous diaphragm stimulation system (in clinical investigation)
An investigational catheter-based system and software designed to provide continual, ventilation-synchronized diaphragm stimulation aimed at achieving physiologic breathing patterns and potentially mitigating ventilator-induced injury; currently evaluated under investigational device protocols.
Services
Clinical trial sponsorship and investigator collaboration
Design and sponsorship of multi-center preclinical and clinical studies (early feasibility, randomized controlled, and pivotal trials) evaluating catheter-based diaphragm neurostimulation; operational collaboration with international clinical sites and investigators.
Clinical trial sponsorship and investigator collaboration
Design and sponsorship of multi-center preclinical and clinical studies (early feasibility, randomized controlled, and pivotal trials) evaluating catheter-based diaphragm neurostimulation; operational collaboration with international clinical sites and investigators.
Expertise Areas
- Diaphragm neurostimulation therapy development
- Transvenous catheter-based device engineering
- Critical care clinical trial design and multi-center execution
- Regulatory strategy and approvals for high-risk medical devices
Key Technologies
- Transvenous phrenic nerve stimulation
- Multi-lumen central venous catheter with integrated electrodes
- ECG-guided catheter placement
- Automated electrode mapping algorithms